Novartis AGNVS
ASignal's systematic analysis rates NVS as Neutral.
Reflects the latest available analysis · analyzed Sep 3, 2026
The case on NVS
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong free cash flow of $11.90B indicates high cash generation ability
- High gross margin of 74.98% reflects strong pricing power and cost control
- Return on equity of 30.35% signals excellent capital efficiency
- MACD above signal line with expanding histogram suggests strengthening upward momentum
- Price above 20-day and 50-day moving averages confirms uptrend
- Revenue growth of 0.80% YoY indicates near-flat top-line expansion
- Earnings declining by 17% YoY raises profitability concerns
- High PEG ratio of 3.37x suggests overvaluation relative to growth
- Current ratio of 0.86x and quick ratio of 0.55x indicate liquidity pressure
- RSI at 65.96 is approaching overbought territory, limiting near-term upside
See the full verdict on NVS
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes NVS
Most investors never get a second opinion, let alone several. ASignal runs NVS past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.